2010 TOWARDS AN HIV CURE WORKSHOP: HIV RESERVOIRS AND STRATEGIES TO CONTROL THEM
Session 3: What is the Role of the Immune System in HIV Persistence?
- Overview Presentation - Can the Immune System Control HIV Reservoirs?
Presenter: Brigette Autran
Pitié – Salpêtrière Institute of Research on Immunity – Cancer and Infection, Paris, France
- Presentation not available
- Abstract Presentation S3.1 - Homeostatic proliferation of memory T – cells and expansion of the HIV – 1 latent reservoir
Presenter: Vincente Planelles
University of Utah, Pathology, Salt Lake City, USA
- Abstract Presentation S3.2 - Systemic immune activation and duodenal CD4+ T - cell depletion are associated with increased proportions of gut Enterobacteriales and Bacteroidales by 16S rDNA sequence analysis in HIV infected subjects
Presenter: David. M. Asmuth
University of California Davis Medical Center, Internal Medicine, Sacaramento, USA
- Abstract Presentation S3.3 - Myeloid dendritic cells induce HIV-1 latency in non – proliferating CD4+ T – cells
Presenter: Vanessa. A. Evans
Monash University, Medicine, Victoria, Australia
- Abstract Presentation S3.4 - Protective HLA alleles limit HIV reservoirs in long – term non – progressors central memory CD4+ T - cells
Presenter: Benjamin Descours
UPMC, Paris VI, umrs945, Paris, France
- Abstract Presentation S3.5 - HIV – 1 elite controllers resist HIV – 1 infection via p21 (cip -1/waf-1)
Presenter: Mathias Lichterfeld
Massachusetts General Hospital, Infectious Disease Division, Boston, USA
Session 4: What Host Factors are at Play?
- Overview speaker - What host factors are at play?
Presenter: Paul de Bakker
Harvard Medical School, Division of Genetics, Boston, USA
- Abstract Presentation S4.1 - Tetherin restricts direct cell – cell viral transfer and transmission of HIV – 1
Presenter: Bjorn Kuhl
McGill University, AIDS Center, Montreal, Canada
- Abstract Presentation S4.2 - The role of the ubiquitin – proteasome pathway in rh TRIM5 restriction of HIV-1
Presenter: Cindy Danielson
Northwestern University, Cell and Molecular Biologz, Chicago, USA
- Abstract Presentation S4.3 - LEDG\p75 is critical but not essential for multiple round HIV – 1 replication
Presenter: Rik Luc Guy Schrijvers
KU Leuven, Molecular Virology and Gene Therapy, Leuven, Belgium
- Abstract Presentation S4.4 - Changes in CD4+ cells miRNA expression following exposure to HIV – 1
Presenter: Claudio Casoli
Università degli Studi di Milano, Dipartimento di Scienye Cliniche, Milano, Italy
Session 5: What are Potential Therapeutic Interventions and How to Evaluate Them?
- Overview speaker - Targeting ‘Residual HIV’ In Its Reservoirs: Where We Are And Where Do We Go?
Presenter: Frank Maldarelli
National Cancer Institute, HIV Drug Resistance Program, Bethesda, USA
- Abstract Presentation S5.1 - Impact of raltegravir on immune reconstitution and thymopoiesis in HIV – 1 – infected patients with undetectable ciremia on HAART
Presenter: Carolina Garrido
Hospital Ramón y Cajal, Madrid, Spain
- Abstract Presentation S5.2 - Effect of 24 – weeks intensification with A CCR5 – antagonist on the decay of the HIV – 1 latent reservoir
Presenter: Carolina Gutierrez
Hospital Ramón y Cajal, Madrid, Spain
- Abstract Presentation S5.3 - Epigenetic drug Gar1041 in combination with antiretroviral therapy (ART) transiently reduces the proviral DNA reservoir in SIVmac251-infected macaques
Presenter: Andrea Savarino
Istituto Superiore di Sanita, Department of Infectious, Parasitic and Immune Diseases, Rome, Italy
- Abstract Presentation S5.4 - Purging the HIV – 1 reservoir through the disruption of the PD-1 pathway
Presenter: Sandrina Da Fonesca
Vaccine and Gene Therapy Institute, Part St Lucie, USA
- Abstract Presentation S5.5 - Measurements of total and integrated HIV DNA demonstrate sporadic blips of unintegrated HIV DNA in HIV+ patients on HAART
Presenter: Una O’Doherty
University of Pennsylvania, Pathology and Laboratory Medicine, Philadelphia, USA
Closing Session: Is Eradication Possible?
- Closing presentation - HIV Reservoirs at AIDS 2010
Presenter: Sharon Lewin
Monash University, Medicine, Melbourne, Australia
- Keynote presentation - Eradication versus Remission: Is Eradication possible?
Presenter: Daria Hazuda
Antiviral and Infectious Disease Basic Research, Merck Research Labs, New Jersey, USA